Skip to main content
SpringerLink
Log in

Intratumor immunologic heterogeneity

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

Tumor cells express a great variety of antigens including tumor specific transplantation antigens, tumorassociated antigens, differentiation antigens, histocompatibilty antigens, lectin-binding sites and receptors for natural killer cells and natural antibodies. These antigens are distributed unevenly on tumor subpopulations and each subpopulation may induce different immune responses to the same determinant. Intratumor immunologic heterogeneity arises early in cancer, possibly during preneoplasia, and exists throughout the course of progression. Metastatic subpopulations are not generally less antigenic than subpopulations within primary tumors. Different arrays of antigenic determinants are displayed by subpopulations but variability in cell surface expression of a single determinant is also a fundamental type of immunologic heterogeneity. Antigenic specificity patterns commonly reveal one-way cross-reactions between tumor subpopulations. Oneway cross-reactions might occur due to quantitative differences, cell-cycle variations, modulation, masking, H-2 expression and restriction phenomena, or alteration in the carbohydrate side-chains of glycoproteins. Interactions which occur when subpopulations co-exist may alter immune responses so that the response to the mixture is not the sum of the responses to the individual subpopulations. It is suggested that the exploitation of the mechanisms involved in immunologic heterogeneity may lead to new therapeutic approaches and that the great diversity of determinants expressed by tumor cells could lead to development of multivalent panel of monoclonal antisera which, acting synergistically, could preferentially lyse tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Woglom WH: Immunity to transplantable tumors. Cancer Rev (4): 9–214, 1929.

    Google Scholar 

  2. Medawar PB: The homograft reaction. Roy Soc London Proc B (148): 145–166, 1958.

    Google Scholar 

  3. Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (18): 769–778, 1957.

    Google Scholar 

  4. Klein G, Klein E: Immune surveillance against virusinduced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci (74): 2121–2125, 1977.

    Google Scholar 

  5. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer (33): 241–259, 1976.

    Google Scholar 

  6. Prehn RT: Antigenic heterogeneity — a possible basis for progression. In: Fourth Bristol-Myers Symp Cancer Res (in press).

  7. Klein G: Tumor antigens. Ann Rev Microbiol (20): 223–252, 1966.

    Google Scholar 

  8. Sjögren HO: Transplantation methods as a tool for detection of tumor-specific antigens. Prog Exp Tumor Res (6): 289–322, 1965.

    Google Scholar 

  9. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive tract. J Exp Med (122): 467–481, 1965.

    Google Scholar 

  10. Vaage J: Nonvirus-associated antigens in virus-induced mouse mammary tumors. Cancer Res (28): 2477–2483, 1968.

    Google Scholar 

  11. Morton DL, Miller GF, Wood DA: Demonstration of tumor-specific immunity against antigens unrelated to the mammary tumor virus in spontaneous mammary adenocarcinomas. J Natl Cancer Inst (42): 289–301, 1969.

    Google Scholar 

  12. Leffell MS, Coggin JHJr: Common transplantation antigens on methylcholanthrene-induced murine sarcomas detected by three assays of tumor rejection. Cancer Res (37): 4112–4119, 1977.

    Google Scholar 

  13. Roberts LK, Lynch DH, Daynes RA: Evidence for two functionally distinct cross-reactive tumor antigens associated with ultraviolet light and chemically induced tumors. Transplantation (33): 352–360, 1982.

    Google Scholar 

  14. Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res (38): 2651–2660, 1978.

    Google Scholar 

  15. Heppner GH, Shapiro WR, Rankin JK: Tumor heterogeneity. Pediatr Oncol (1): 99–116, 1981.

    Google Scholar 

  16. Kripke ML, Gruys E, Fidler IJ: Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res (38): 2962–2967, 1978.

    Google Scholar 

  17. Kerbel RS: Implications of immunological heterogeneity of tumours. Nature (280): 358–360, 1979.

    Google Scholar 

  18. Prehn RT: Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J Natl Cancer Inst (45): 1039–1045, 1970.

    Google Scholar 

  19. Colnaghi MI, Ménard S, Della Porta G: Natural antitumor serum reactivity in BALB/c mice. II. Control by regulator T-cells. Int J Cancer (19): 275–280, 1977.

    Google Scholar 

  20. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci (66): 1089–1095, 1970.

    Google Scholar 

  21. Mihich E, Kitano M: Differences in the immunogenicity of leukemia L1210 sublines in DBA/2 mice. Cancer Res (31): 1999–2003, 1971.

    Google Scholar 

  22. Nicolin A, Vadlamudi S, Goldin A: Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res (31): 653–657, 1972.

    Google Scholar 

  23. Fuji H, Mihich E: Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay. Cancer Res (35): 946–952, 1975.

    Google Scholar 

  24. Fuji H, Mihich E, Pressman D: Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro. J Immunol (119): 983–986, 1977.

    Google Scholar 

  25. Fuji H, Mihich E, Pressman D: Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods. J Natl Cancer Inst (62): 1503–1510, 1979.

    Google Scholar 

  26. Fuji H: Monoclonal antibody recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines. Transpl Proc (12): 388–390, 1980.

    Google Scholar 

  27. Rapp L, Fuji H: Differential antigenic expression of the DBA/2 lymphoma L1210 and its subline cells and cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibody. Proc Am Assoc Cancer Res (23): 270, 1982 (Abstr).

    Google Scholar 

  28. Stuck B, Boyse EA, Old LJ, Carswell EA: ML: a new antigen found in leukemias and mammary tumors of the mouse. Nature (203): 1033–1034, 1964.

    Google Scholar 

  29. Nicolin A, Marelli O, Franco P, Goldin A: DTIC-induced antigens in clone lines of L1210 leukemia. Proc Am Assoc Cancer Res (23): 270, 1982 (Abstr).

    Google Scholar 

  30. Killion JJ: Immunotherapy with tumor cell subpopulations. I. Active, specific immunotherapy of L1210 leukemia. Cancer Immunol Immunother (4): 115–119, 1978.

    Google Scholar 

  31. Miller FR, Heppner GH: Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst (63): 1457–1463, 1979.

    Google Scholar 

  32. Wang N, Yu SH, Liener IE, Hebbel RP, Eaton JW, McKhann CF: Characterization of high- and low-metastatic clones derived from a methylcholanthrene-induced murine fibrosarcoma. Cancer Res (42): 1046–1051, 1982.

    Google Scholar 

  33. Reddy AL, Fialkow PJ: Multicellular origin of fibrosarcomas in mice induced by the chemical carcinogen 3-methylcholanthrene. J Exp Med (150): 878–887, 1979.

    Google Scholar 

  34. DeBaetselier P, Katzav S, Gorelik E, Feldman M, Segal S: Differential expression of H-2 gene products in tumour cells is associated with their metastatogenic properties. Nature (288): 179–181, 1980.

    Google Scholar 

  35. Faraci RP: In vitro demonstration of altered antigenicity of metastases from a primary methylcholanthrene-induced sarcoma. Surgery (76): 469–473, 1974.

    Google Scholar 

  36. Fritze D, Kern DH, Humme JA, Drogemuller CR, Pilch YH: Detection of private and common tumor-associated antigens in murine sarcomas induced by different chemical carcinogens. Int J Cancer (17): 138–147, 1976.

    Google Scholar 

  37. Haywood GR, McKhann CF: Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J Exp Med (133): 1171–1187, 1971.

    Google Scholar 

  38. Pellis NR, Tanaka T, Inaba S: Clonal analysis of tumor antigen expression. Proc Am Assoc Cancer Res (23): 276, 1982 (Abstr).

    Google Scholar 

  39. Pimm MV, Embleton MJ, Baldwin RW: Multiple antigenic specificities within primary 3-methylcholanthrene-induced rat sarcomas and metastases. Int J Cancer (25): 621–629, 1980.

    Google Scholar 

  40. Pimm MV, Baldwin RW: Antigenic differences between primary methylcholanthrene-induced rat sarcomas and post-surgical recurrences. Int J Cancer (20): 37–43, 1977.

    Google Scholar 

  41. Schmitt M, Daynes RA: Heterogeneity of tumorigenicity phenotype in murine tumors. Transplantation (33): 387–392, 1982.

    Google Scholar 

  42. Tanaka T, Pellis NR: Antigens of sublines derived from a methylcholanthrene (MCA)-induced fibrosarcoma. Proc Am Assoc Cancer Res (22): 299, 1981 (Abstr).

    Google Scholar 

  43. Tanooka H, Tanaka K: Evidence for single-cell origin of 3-methylcholanthrene-induced fibrosarcomas in mice with cellular mosaicism. Cancer Res (42): 1856–1858, 1982.

    Google Scholar 

  44. Pfreundschuh M, Cravioto H: Serological analysis of nitrosourea-induced rat gliomas. Proc Am Assoc Cancer Res (22): 294, 1981 (Abstr).

    Google Scholar 

  45. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H: Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med (155): 557–573, 1982.

    Google Scholar 

  46. Key ME, Hanna MGJr.: Antigenic heterogeneity of the guinea pig line 10 hepatocarcinoma. Implications for active specific immunotherapy. Cancer Immunol Immunother (12): 211–215, 1982.

    Google Scholar 

  47. Sloane JP, Ormerod MG: Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer (47): 1786–1795, 1981.

    Google Scholar 

  48. Nuti P, Horan Hand P, Colcher D, Schlom J: Monoclonal antibodies to tumor-associated antigens (TAAs) define heterogeneity of human mammary tumors. Proc Am Assoc Cancer Res (23): 267, 1982 (Abstr).

    Google Scholar 

  49. Byers VS, Johnston JO: Antigenic differences among osteogenic sarcoma tumor cells taken from different locations in human tumors. Cancer Res (37): 3173–3183, 1977.

    Google Scholar 

  50. Wikstrand CJ, Bigner SP, Bigner DD: Antigenic heterogeneity of an established human glioma cells line (HGCL) and eight single cell derived clones as defined by specific anti-glioma monoclonal antibodies. Proc Am Assoc Cancer Res (23): 271, 1982 (Abstr).

    Google Scholar 

  51. Kim U: Metastasizing mammary carcinomas in rats: induction and study of their immunogenicity. Science (167): 72–74, 1970.

    Google Scholar 

  52. Sugarbaker EV, Cohen AM: Altered antigenicity in spontaneous pulmonary metastases from an antigenic murine sarcoma. Surgery (72): 155–161, 1972.

    Google Scholar 

  53. Sugarbaker EV, Cohen AM, Ketcham AS: Concomitant tumor immunity and immunoselection of metastases. Curr Top Surg (3): 349–361, 1971.

    Google Scholar 

  54. Brodt P, Segal S: Studies on the antigenic heterogeneity of the Lewis lung carcinoma (3LL). Proc Am Assoc Cancer Res (22): 299, 1981 (abstr).

    Google Scholar 

  55. Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hübsch D: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Int J Cancer (23): 245–252, 1979.

    Google Scholar 

  56. Bosslet K, Schirrmacher V, Shantz G: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective antitumor immunity in vivo and of cytolytic T cells in vitro. Int J Cancer (24): 303–313, 1979.

    Google Scholar 

  57. Proctor JW, Palmer P, Rudenstam C-M: Transplantation isoantigenicity of a rat sarcoma and its spontaneous metastases. J Natl Cancer Inst (53): 579–580, 1974.

    Google Scholar 

  58. Fogel M, Gorelik E, Segal S, Feldman M: Differences in cell surface antigens of tumor metastases and those of the local tumor. J Natl Cancer Inst (62): 585–588, 1979.

    Google Scholar 

  59. Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (154): 1764–1778, 1981.

    Google Scholar 

  60. Mantovani A, Giavazzi R, Alessandri G, Spreafico F, Garattini S: Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. Eur J Cancer (17): 71–76, 1981.

    Google Scholar 

  61. Slemmer GL: Interactions of different types of mammary cells during progression and metastasis of breast neoplasia. In: CM McGrath, MJ Brennan, MA Rich (eds) Cell biology of breast cancer. Academic Press, New York, pp 93–143, 1980.

    Google Scholar 

  62. Lappé MA: Possible significance of immune recognition of preneoplastic and neoplastic cell surfaces. Natl Cancer Inst Monogr (35): 49–55, 1972.

    Google Scholar 

  63. Boone CW, Vembu D, White BJ, Takeichi N, Paraujpe M: Karyotypic, antigenic, and kidney-invasive properties of cell lines from fibrosarcomas arising in C3H/10T1/2 cells implanted subcutaneously attached to plastic plates. Cancer Res (39): 2172–2178, 1979.

    Google Scholar 

  64. Lappé MA: Tumor specific transplantation antigens: possible origin in pre-malignant lesions. Nature (223): 82–84, 1969.

    Google Scholar 

  65. Medina D: Preneoplastic lesions in mouse mammary tumorigenesis. Meth Cancer Res (7): 3–53, 1973.

    Google Scholar 

  66. Ruppert B, Wei W, Medina D, Heppner GH: Effect of chemical carcinogen treatment of the immunogenicity of mouse mammary tumors arising from hyperplastic alveolar nodule outgrowth lines. J Natl Cancer Inst (61): 1165–1169, 1978.

    Google Scholar 

  67. Slemmer G: Host response to premalignant mammary tissues. Natl Cancer Inst Monogr (35): 57–71, 1972.

    Google Scholar 

  68. Heppner GH, Kopp JS, Medina D: Microcytotoxicity assay of immune responses to non-mammary tumor virus-induced, preneoplastic, and neoplastic mammary lesions in BALB/c mice. Cancer Res (36): 753–758, 1976.

    Google Scholar 

  69. Miller FR, Blazkovec AA: Guinea pig cell-mediated tumor immunity: the chromium release assay detects both cytolysis and serum blocking for syngeneic chemically-induced tumors. Immunol Commun (8): 31–47, 1979.

    Google Scholar 

  70. Miller BE, Miller FR, Leith J, Heppner GH: Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res (40): 3977–3981, 1980.

    Google Scholar 

  71. Globerson A, Feldman M: Antigenic specificity of Benzo[a]pyrene-induced sarcomas. J Natl Cancer Inst (32): 1229–1243, 1964.

    Google Scholar 

  72. Boon T, Kellerman O: Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci (74): 272–275, 1977.

    Google Scholar 

  73. Boon T, Van Pel A: Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci (75): 1519–1523, 1978.

    Google Scholar 

  74. Georlette M, Boon T: Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor. Eur J Cancer Clin Oncol (17): 1083–1087, 1981.

    Google Scholar 

  75. Vaage J: A survey of the growth characteristics of and the host reactions to one hundred C3H/He mammary carcinomas. Cancer Res (38): 331–338, 1978.

    Google Scholar 

  76. Fenyo EM, Klein E, Klein G, Swiech K: Selection of an immunoresistant Moloney lymphoma subline with decreased concentration of tumor-specific surface antigens. J Natl Cancer Inst (40): 69–89, 1968.

    Google Scholar 

  77. Cikes M, Friberg SJr, Klein G: Quantitative studies of antigen expression in cultured murine lymphoma cells. II. Cell-surface antigens in synchronized cultures. J Natl Cancer Inst (49): 1607–1611, 1972.

    Google Scholar 

  78. Cikes M, Klein G: Quantitative studies of antigen expression in cultured murine lymphoma cells. I. Cellsurface antigens in ‘asynchronous’ cultures. J Natl Cancer Inst (49): 1599–1606, 1972.

    Google Scholar 

  79. Everson LK, Plocinik BA, Rogentine GNJr: HL-A expression on the G1, S, and G2 cell-cycle stages of human lymphoid cells. J Natl Cancer Inst (53): 913–920, 1974.

    Google Scholar 

  80. Lerner RA, Oldstone MBA, Cooper NR: Cell-cycle-dependent immune lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to antibody, and complement activation. Proc Natl Acad Sci (68): 2584–2588, 1971.

    Google Scholar 

  81. Panem S, Schauf V: Cell-cycle dependent appearance of murine leukemia-sarcoma virus antigens. J Virol (13): 1169–1175, 1974.

    Google Scholar 

  82. Pasternak CA, Warmsley AMH, Thomas DB: Structural alterations in the surface membrane during the cell cycle. J Cell Biol (50): 562–564, 1971.

    Google Scholar 

  83. Shipley WU: Immune cytolysis in relation to the growth cycle of Chinese hamster cells. Cancer Res (31): 925–929, 1971.

    Google Scholar 

  84. Ohanian SH, Borsos T, Rapp HJ: Lysis of tumor cells by antibody and complement. I. Lack of correlation between antigen content and lytic susceptibility. J Natl Cancer Inst (50): 1313–1320, 1973.

    Google Scholar 

  85. Barker CF, Billingham RE: Immunologically privileged sites. Adv Immunol (25): 1–54, 1977.

    Google Scholar 

  86. Blair PB, Moretti RL: The mammary fatpad as a privileged transplantation site. Transplantation (5): 542–544, 1967.

    Google Scholar 

  87. den Oter W, Runhaar A, Ruitenbeek BA, Dullens HFJ: Site-dependent differences in rejection of tumor cells with and without preimmunization. Eur J Immunol (4): 444–446, 1974.

    Google Scholar 

  88. Hamilton MS, Billingham RE: Privileged status of the subcutaneous site for skin allografts in rats. Transplantation (28): 199–202, 1979.

    Google Scholar 

  89. Miller FR, Heppner GH: Tumor immunity in the mammary gland. Cancer Immunol Immunother (12): 173–176, 1982.

    Google Scholar 

  90. Miller FR, Medina D, Heppner GH: Preferential growth of mammary tumors in intact mammary fatpads. Cancer Res (41): 3863–3867, 1981.

    Google Scholar 

  91. Robert F, Oth D, Berebbi M: Obtention of 7 ascites tumor lines expressing H-2s and not H-2k from a C3H-specific polyoma-induced solid tumor. Transpl Proc (13): 1828–1832, 1981.

    Google Scholar 

  92. Hilgers J, Sonnenberg A, Nusse R: Antigenic modulation of mammary tumor virus envelope antigen on GR thymic lymphoma cells in relation to expression of H-2, TL cellsurface antigens, and THY-1. Br J Cancer (42): 542–550, 1980.

    Google Scholar 

  93. Old LJ, Stockert E, Boyse EA, Kim JH: Antigenic modulation. Loss of TL antigens from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (127): 523–539, 1968.

    Google Scholar 

  94. Stackpole CW: Modulation of thymus-leukemia antigens on mouse leukemia cells induced by IgG, but not IgM, antibody, J Natl Cancer Inst (64): 917–923, 1980.

    Google Scholar 

  95. Kerbel RS: Immunologic studies of membrane mutants of a highly metastatic murine tumor. Am J Pathol (97): 609–622, 1979.

    Google Scholar 

  96. Shearer WT, Gottlieb C, Kornfeld S: Humoral immunostimulation. VII. Sialic acid masks antigenic sites on an antibody-selected variant cell line. J Immunol (119): 614–617, 1977.

    Google Scholar 

  97. Simmons RL, Rios A: Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas. J Immunol (111): 1820–1825, 1973.

    Google Scholar 

  98. Simmons RL, Rios A, Kersey JH: Regression of spontaneous mammary carcinomas using direct injections of neuraminidase and BCG. J Surg Res (12): 57–61, 1972.

    Google Scholar 

  99. Friberg SJr: Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. II. Immunosensitivity and antibody-binding capacity in vitro, and immunogenicity in allogeneic mic. J Natl Cancer Inst (48): 1477–1489, 1972.

    Google Scholar 

  100. Barz D, Bosslet K, Schirrmacher V: Metastatic tumor cell variants with increased resistance to infection by Semliki forest virus. J Immunol (127): 951–954, 1981.

    Google Scholar 

  101. Parmiani G, Carbone G, Invernizzi G, Pierotti MA, Sensi ML, Rogers MJ, Appella E: Alien histocompatibility antigens on tumor cells. Immunogenetics (9): 1–24, 1979.

    Google Scholar 

  102. Schirrmacher V, Robinson P, Altevogt P, Radbruch A, Garrido F, Koszinowski U, Krog H-H, Lundin L: Clonal analysis of H-2 antigen expression by variants of a chemically induced murine tumor. Transpl Proc (13): 1819–1823, 1981.

    Google Scholar 

  103. Koszinowski U, Ertl H: Lysis mediated by T cells and restricted by H-2 antigen of target cells infected with vaccinia virus. Nature (255): 552–554, 1975.

    Google Scholar 

  104. Zinkernagel RM: H-2 compatibility requirement for virus-specific T-cell-mediated cytolysis. The H-2K structure involved is coded by a single cistron defined by H-2Kb mutant mice. J Exp Med (143): 437–443, 1976.

    Google Scholar 

  105. Greenberg PD, Cheever MA, Fefer A: H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol (126): 2100–2103, 1981.

    Google Scholar 

  106. Schrader JW, Cunningham BA, Edelman GM: Functional interactions of viral and histocompatibility antigens at tumor cell surfaces. Proc Natl Acad Sci (72): 5066–5070. 1975.

    Google Scholar 

  107. Germain RN, Dorf ME, Benacerraf B: Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificites of the tumor. J Exp Med 142: 1023–1028, 1975.

    Google Scholar 

  108. Schrader JW, Edelman GM: Participation of the H-2 antigens of tumor cells in their lysis by syngeneic T-cells. J Exp Med 143: 601–614, 1976.

    Google Scholar 

  109. Forni G, Shevach EM, Green I: Mutant lines of guinea pig L2C leukemia. I. Deletion of 1a alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens. J Exp Med 143: 1067–1081, 1976.

    Google Scholar 

  110. Schmitt-Verhulst A-M, Sachs DH, Shearer GM: Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Confirmation of genetic control of response to trinitrophenyl-modified H-2 antigens by the use of anti-H2 and anti-1a antibodies. J Exp Med 143: 211–217, 1976.

    Google Scholar 

  111. Schmitt-Verhulst A-M, Shearer GM: Multiple H-2 linked immune response gene control of H-2D-associated T-cell-mediated lympholysis to trinitrophenyl-modified autologous cells: Ir-like genes mapping to the left of I-A and within the I region. J Exp Med (144): 1701–1706, 1976.

    Google Scholar 

  112. Shearer GM, Rehn TG, Garbarino CA: Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by the H-2K and H-2D serological regions of the murine major histocompatibility complex. J Exp Med (141): 1348–1364, 1975.

    Google Scholar 

  113. Hellström KE: Studies on allogeneic inhibition. I. Differential behavior of tumor transplanted to homozygous and F1 hybrid hosts. Int J Cancer (1): 349–359, 1966.

    Google Scholar 

  114. Williams RM, Dorf ME, Benacerraf B: H-2-linked genetic control of resistance to histocompatible tumors. Cancer Res (35): 1586–1590, 1975.

    Google Scholar 

  115. Finne J, Tao T-W, Burger MM: Carbohydrate changes in glycoproteins of a poorly metastasizing wheat germ agglutinin-resistant melanoma clone. Cancer Res (40): 2580–2587, 1980.

    Google Scholar 

  116. Killion JJ, Kollmorgen GM: Isolation of immunogenic tumour cells by cell-affinity chromatography. Nature 259: 674–676, 1976.

    Google Scholar 

  117. Killion JJ, Wallenbrock MA, Rogers JAIII, Kollmorgen GM, Sansing WA, Cantrell JL: Tumorigenicity and the expression of cell-surface carbohydrates. Nature (261): 54–56, 1976.

    Google Scholar 

  118. Price JE, Tarin D: Lectin agglutinability of mammary tumours with differing metastatic colonisation potentials. Differentiation (20): 264–269, 1981.

    Google Scholar 

  119. Lavrovski VA, Viksler VK: Immunological properties of malignant and nonmalignant sublines of L-cells. Cancer Res (40): 3252–3258, 1980.

    Google Scholar 

  120. Grönberg A, Kiessling R, Eriksson E, Hansson M: Variants from a MLV-induced lymphoma selected for decreased sensitivity to NK lysis. J Immunol (127): 1734–1739, 1981.

    Google Scholar 

  121. Chow DA, Miller VE, Carlson GA, Pohajdak B, Greenberg AH: Natural resistance to tumors is a heterogeneous immunological phenomenon. Evidence for non-NK cell mechanisms. Invasion Metastasis (1): 205–219, 1981.

    Google Scholar 

  122. Gorelik E, Feldman M, Segal S: Selection of 3LL tumor subline resistant to natural effector cells concomitantly selected for increased metastatic potency. Cancer Immunol Immunother (12): 105–109, 1982.

    Google Scholar 

  123. Takasugi M, Koide Y, Akira D, Ramseyer A: Specificities in natural cell-mediated cytotoxicity by the cross-competition assay. Int J Cancer (19): 291–297, 1977.

    Google Scholar 

  124. Roder JC, Ahrlund-Richter L, Jondal M: Target-effector interaction in the human and murine natural killer system. Specificity and xenogeneic reactivity of the solubilized natural killer-target structure complex and its loss in a somatic cell hybrid. J Exp Med (150): 471–481, 1979.

    Google Scholar 

  125. Zaunders J, Werkmeister J, McCarthy WH, Hersey P: Characterization of antigens recognized by natural killer cells in cell-culture supernatants. Br J Cancer (43): 5–12, 1981.

    Google Scholar 

  126. Gidlund M, Örn A, Pattengale PK, Jansson M, Wigzell H, Nilsson K: Natural killer cells kill tumour cells at a given stage of differentiation. Nature (292): 848–850, 1981.

    Google Scholar 

  127. Werkmeister J, Helfand SL, Haliotis T, Rubin P, Pross H, Roder J: Tumor cell differentiation modulates susceptibility to natural killer cells. Cell Immunol (69): 122–127, 1982.

    Google Scholar 

  128. Clark EA, Sturge JC, Falk LAJr: Induction of target antigens and conversion to susceptible phenotype of NK-cell-resistant lymphoid cell line. Int J Cancer (28): 647–654, 1981.

    Google Scholar 

  129. Chow DA, Wolosin LB, Greenberg AH: Murine natural anti-tumor antibodies. II. The contribution of natural antibodies to tumor surveillance. Int J Cancer (27): 459–469, 1981.

    Google Scholar 

  130. Fidler IJ: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science (208): 1469–1471, 1980.

    Google Scholar 

  131. Loveless SE, Munson AE, Heppner GH: Tumoricidal macrophages isolated from murine mammary tumors that differ in biological behavior. Proc Am Assoc Cancer Res (23): 262, 1982 (abstr).

    Google Scholar 

  132. Mantovani A: Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity. Int J Cancer (22): 741–746, 1978.

    Google Scholar 

  133. Berd D, Mastrangelo MJ: Differential sensitivity of two murine leukemia sublines to cytolysis by Corynebacterium parvum-activated macrophages. Br J Cancer (44): 819–827, 1981.

    Google Scholar 

  134. Nicolson GL, Reading CL, Mascali JJ, McGuire EJ: The role of viral and oncofetal antigens in murine lymphosarcoma metastasis to specific sites. Proc Am Assoc Cancer Res (23): 47, 1982 (abstr).

    Google Scholar 

  135. Wolosin LB, Greenberg AH: Murine natural anti-tumor antibodies. I. Rapid in vivo binding of natural antibody by tumor cells in syngeneic mice. Int J Cancer (23): 519–529, 1979.

    Google Scholar 

  136. Colnaghi MI, Ménard S, Tagliabue E, Torre GD: Heterogeneity of the natural humoral anti-tumor immune response in mice as shown by monoclonal antibodies. J Immunol (128): 2757–2762, 1982.

    Google Scholar 

  137. Hellström I, Brown JP, Hellström KE: Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity. J Immunol (127): 157–160, 1981.

    Google Scholar 

  138. Roberts LK, Spellman CW, Daynes RA: Modulation of immunoregulatory responses directed toward various tumor antigens within hosts possessing distinct immunologic potentials. J Immunol (125): 663–672, 1980.

    Google Scholar 

  139. Miller BE, Miller FR, Heppner GH: Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res (41): 4378–4381, 1981.

    Google Scholar 

  140. Nowotny A, Grohsman J: Mixed tumor challenge of strain specific and nonspecific TA3 mouse ascites mammary adenocarcinoma. Int Arch Allergy (44): 434–440, 1973.

    Google Scholar 

  141. Olsson L, Ebbesen P: Natural polyclonality of spontaneous AKR leukemia and its consequences of so-called specific immunotherapy. J Natl Cancer Inst (62): 623–627, 1979.

    Google Scholar 

  142. Al-Ghazzouli IK, Donahoe RM, Huang K-Y, Sass B, Peters RL, Kelloff GJ: Immunity to virus-free syngeneic tumor cell transplantation with homologous tumor cells infected with Type C virus. J Immunol (117): 2239–2248, 1976.

    Google Scholar 

  143. Miller FR, Heppner GH: Intratumor immunologic interactions. Proc Am Assoc Cancer Res (21): 201, 1980 (abstr).

    Google Scholar 

  144. Poste G, Doll J, Fidler IJ: Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci (78): 6226–6230, 1981.

    Google Scholar 

  145. Taupier MA, Loken MR, Kearney JF, Leibson PJ, Schreiber H: Nonheritable heterogeneity in amount of tumor antigen expression within tumor clones and its effect on immune lysis. Proc Am Assoc Cancer Res (22): 294, 1981 (abstr).

    Google Scholar 

  146. Fidler IJ: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science (208): 1469–1471, 1980.

    Google Scholar 

  147. Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G: Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res (42): 496–501, 1982.

    Google Scholar 

  148. Fidler IJ, Sone S, Fogler WE, Barnes Z: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci (78): 1680–1684, 1981.

    Google Scholar 

Download references

Author information

Author notes

  1. Fred R. Miller

    Present address: Department of Immunology, Michigan Cancer Foundation, 110 E. Warren Ave., 48201, Detroit, MI, USA

Authors and Affiliations

  1. Department of Immunology, Michigan Cancer Foundation, 48201, Detrolt, Michigan, USA

    Fred R. Miller

Authors
  1. Fred R. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, F.R. Intratumor immunologic heterogeneity. Cancer Metast Rev 1, 319–334 (1982). https://doi.org/10.1007/BF00124215

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00124215

Keywords

Search

Navigation